Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK-432,097 dry powder inhalation in moderate to severe COPD
NL-OMON30744Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing UK-432,097 DPI with Placebo DPI (2 arms). Primary endpoint: Change from baseline in trough FEV1 at Week 6. Started Jul 2007; status: active, not recruiting.
02
Drugs
UK-432097
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON30744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30744.